PMID- 34139730
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 48
IP  - 6
DP  - 2021 Jun
TI  - [Retrospective Analysis of Bortezomib or Lenalidomide for Very Elderly Patients 
      with Newly Diagnosed Multiple Myeloma].
PG  - 815-819
AB  - In elderly patients aged>/=80 with newly diagnosed multiple myeloma(NDMM), the 
      optimal initial doses of bortezomib (Bor)and lenalidomide(Len)remain unclear. We 
      performed a retrospective analysis that included 20 patients with NDMM aged>/=80 
      years who underwent treatment with Bor or Len at our hospital from July 2010 to 
      December 2019. Among the patients treated with Bor, the median time to next 
      treatment(TTNT)was 4.2 months, and the median dose was 1.0 mg/m2 per injection. 
      While patients with International Staging System(ISS)Ⅲ or an estimated glomerular 
      filtration rate of < 40 mL/ min/1.73 m2 required dose reductions, dose intensity 
      did not significantly affect TTNT. Among the patients treated with Len, the 
      median TTNT was 14.6 months, and the median dose of Len was 10.0 mg/day. All 
      patients who started with6le;10 mg Len continued the initial dose; the others 
      required a dose reduction. Treatment was discontinued in 2 patients because of 
      disease progression and in other 15 patients because of adverse events(AEs). In 
      conclusion, initial doses of Bor at 1.0 mg/ m2 per injection and Len at 10 mg per 
      day may provide potent disease control and permit continuing treatment with few 
      AEs in elderly patients with MM.
FAU - Okayama, Yusuke
AU  - Okayama Y
AD  - Dept. of Hematology, Osaka Saiseikai Nakatsu Hospital.
FAU - Takakuwa, Teruhito
AU  - Takakuwa T
FAU - Otomaru, Ippei
AU  - Otomaru I
FAU - Horiuchi, Mirei
AU  - Horiuchi M
FAU - Miura, Akiko
AU  - Miura A
FAU - Araki, Taku
AU  - Araki T
FAU - Fujitani, Yotaro
AU  - Fujitani Y
FAU - Yamamura, Ryosuke
AU  - Yamamura R
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 69G8BD63PP (Bortezomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Bortezomib/adverse effects
MH  - Dexamethasone/therapeutic use
MH  - Humans
MH  - Lenalidomide/therapeutic use
MH  - *Multiple Myeloma/drug therapy
MH  - Retrospective Studies
EDAT- 2021/06/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/06/17 20:30
PHST- 2021/06/17 20:30 [entrez]
PHST- 2021/06/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2021 Jun;48(6):815-819.